Exhibit 99.1 Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights -Contineum is focused on leading the Neuroscience, Inflammation and Immunology (NI&I) field- -Successful completion of Initial Public Of ering with strong syndicate of existing and new investors- SAN DIEGO, May 16, 2024 (Business Wire) — Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies ...